Voyager Acquisition Corp (VACH) is a forward-thinking special purpose acquisition company (SPAC) committed to identifying and merging with innovative technology firms that are leading the charge in digital transformation and sustainability. With a seasoned management team that possesses substantial expertise in finance and operational integration, VACH strategically targets high-growth opportunities within the fast-evolving tech landscape. As the appetite for cutting-edge technological solutions intensifies, Voyager is well-positioned to establish transformative partnerships that are likely to enhance shareholder value and leverage emerging market trends effectively.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.87% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.42 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -91.10% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $25.30M |
| Float | 82,660 |
| % Insiders | 1.08% |
| % Institutions | 10.46% |
Volatility is currently expanding
The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and NASDAQ trading of $VRXA commences on June 11, 2026.
VERAXA Biotech AG has strengthened its financial position to position to support the closing of its business combination with Voyager Acquisition Corp.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VACH and any ticker you trade — then tracks every position and per-strategy win rate.
